Can triple-negative breast cancer be treated with PARP inhibitors?

Can triple-negative breast cancer be treated with PARP inhibitors?
Sepideh Abdollahi,¹ Pantea Izadi,^2,*
1. Tehran university of medical sciences
2. Tehran university of medical sciences
Introduction: Poly (ADP-Ribose) Polymerase 1 (PARP1) is an enzyme with a key role in the recovery of cells from DNA damage. There are pieces of evidence concerning the positive therapeutic efficiency of PARP1 inhibitor in breast cancer with or without mutation in BRCA. Therefore, evaluation of the PARP1 inhibitor as a new targeted therapy has been considered in triple-negative breast cancer (TNBC). TNBC is a heterogeneous subtype of breast cancer with aggressive clinical behavior and negative expression of ER, PR and Her2 results in a lack of targeted therapy.
Methods: Published scientific literature and clinical trials concerning the importance of PARP1 inhibitor in breast cancer with mutation in genes other than BRCA and sporadic TNBC were reviewed from 2000 to 2020. Searches were carried out using Goole scholar and Pub Med.
Results: According to the results, although PARP1 inhibitor therapy predominantly targeted breast cancer with a germline mutation in BRCA, it also can have positive therapeutic efficiency in breast cancer with somatic mutation in BRCA, the mutation in genes other than BRCA or exhibited BRCAness.
Conclusion: PARP1 inhibitor in cancers with beyond BRCA-mutant showed promising results to be considered as targeted therapy. These findings would provide a strategy for expanding the clinical trials on PARP1 inhibitor-based therapy in sporadic TNBC.
Keywords: triple-negative breast cancer; sporadic TNBC; targeted therapy; PARP1 inhibitor